Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 902 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
The use of complementary medicines, such as plant extracts, in dementia therapy varies according to the different cultural traditions.
-
Dementia with Lewy bodies (DLB) is common.
-
The data from the present study do not lend support to the idea that low affinity, open channel NMDA receptor blockers are also effective in models of epilepsy at doses having little effect on physiological processes.
-
Limited information is available regarding the incidence, nature, and treatment of behavioral problems in Alzheimer's disease (AD).
-
Necropsy brain tissue from normal (control) patients and patients with depression and dementia was examined for activities of various cholinergic components, and these related to the degree of senile plaque formation and extent of intellectual impairment.
-
Acetyl- and butyryl-cholinesterase activities have been measured biochemically in normal brain tissue, in senile dementia of Alzheimer type and in mental disorders without Alzheimer-type abnormalities.
-
Three new drugs are presented: dostarlimab, loncastuximab tesirine, and aducanumab.
-
39/100
Alzheimer’s disease is a major cause of morbidity and mortality.
-
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA).
-
Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease.
-
Alzheimer’s disease (AD) is the most common form of dementia with global burden projected to triple by 2050.
-
En junio, la Agencia de Alimentos y medicamentos de los Estados Unidos (FDA) otorgó aprobación mediante vía acelerada al medicamento aducanumab, desarrollado por Biogen, Inc. para tratamiento de la enfermedad de Alzheimer (EA).
-
On 7 June , the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.
-
Aducanumab has recently been licensed by the Food and Drug Administration (FDA) in the USA under its ‘accelerated approval’ pathway (to provide earlier access to treatments that fulfil an unmet need based on a surrogate endpoint) for treatment of Alzheimer's disease.
-
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its accelerated approval pathway.
-
Patients with early symptomatic Alzheimer's disease showed less cognitive and functional decline with donanemab compared with placebo in a Phase 2 study offering up to 72 weeks of treatment.
-
With the approval of aducanumab on the “Accelerated Approval Pathway” and the recognition of amyloid load as a surrogate marker, new successful therapeutic approaches will be driven by combination therapy as was the case in oncology after the launch of immune checkpoint inhibitors.
-
39/100
It is important to have a wide perspective to provide appropriate medical care for the oldest-old individuals.
-
Insomnia and hypersomnia are conditions with multifactorial causes that can be difficult to treat.
-
Metformin was originally derived from a botanical ancestry and became the most prescribed, first-line therapy for Type 2 diabetes in most countries.
-
Alzheimer's disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people.
-
We identified 53 clinical trials involving 58 FDA-approved agents.
-
Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD).
-
The history of medical and psychiatric use of lithium dates back to more than one and a half-century ago.
-
Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue.
From across this topic
9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
- A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase
- Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
- The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
- Tryptamine: A privileged scaffold for the management of Alzheimer's disease
- Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions
- The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset
- Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications
- Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia